Rosetta Genomics, Ltd. ROSG announced today that it has joined the Rimonim pharmaceutical consortium. The goal of the consortium, which is funded by the Office of the Israeli Chief Scientist, is to bring together leading Israeli biotechnology companies in order to advance RNAi-based therapeutics.
By joining the consortium Rosetta Genomics received a $460,000 grant from the OCS.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in